Emerging roles of Semaphorins in the regulation of epithelial and endothelial junctions

Lucas Treps,1,2,3 Armelle Le Guelte1,2,3 and Julie Gavard1,2,3,*

1CNRS; UMR8104; Paris, France; 2Inserm; U1016; Paris, France; 3Université Paris Descartes; Sorbonne Paris Cité; Paris, France

Keywords: cadherin, tight junction, permeability, barrier, semaphorin

Historically characterized for their roles in the developing central nervous system (CNS), Semaphorins have emerged as multifaceted guidance proteins that control biological responses in the epithelia and endothelia under physiological and pathological circumstances. In this review, we discuss their influence and mode of action in the regulation of tissue barriers, especially at the level of intercellular junctions.

Vertebrate Semaphorins and their Receptors

Semaphorins were identified more than 20 years ago as proteins, which provide a wide repertoire of attractive and repulsive signals that orchestrate axon outgrowth.1,2 A large number of these guidance molecules combines with multiple receptors and co-receptors, increasing thereby both specificity and complexity of the Semaphorin mode of action (Fig. 1). Therefore, the elucidation of signaling cascades activated by these molecules is the subject of intense research.

Semaphorins. In vertebrates, there are 20 semaphorin genes,2 sub-divided into classes III–VII. Class III semaphorins (Sema3A–G) are secreted, while Semaphorins from subclasses IV–VI exist as transmembrane proteins and Sema7A contains a glycosylphosphatidylinositol (GPI) anchor. Each Semaphorin possesses a 500 amino acid extracellular domain, called semaphorin (sema) composed of a seven-bladed β propeller domain, essential for signaling. This domain is followed by a cysteine-rich domain (PSI), involved in receptor binding ability.3 Conversely, the C-terminal tail features additional sequence motifs that diverge among classes: class III contains both an immunoglobulin-like and a basic residue-rich domains, whereas class V are distinguished by thrombospondin repeats4 (Fig. 1). Semaphorins co-opt two kinds of transmembrane receptors (Plexins and Neuropilins), which mediate downstream signaling.

Plexins. Plexins are the main cell surface receptors for Semaphorin signal transduction. Plexins comprise nine members in mammals and are subdivided into four classes: class A (A1–4), class B (B1–3), PlexinC1 and PlexinD15 (Fig. 1). Unlike Semaphorins, Plexin architecture is conserved throughout the family. The extracellular region is composed by one sema domain and two or three PSI and IPT (immunoglobulin shared by Plexins and transcription factors) repeats. Class III and VI Semaphorins mainly bind to PlexinA. Most of the class III Semaphorins require a co-receptor from the Neuropilin family (NRP, see paragraph 1.3), while the class VI Semaphorins directly interact with PlexinA through their respective sema domains, which in turn conveys intracellular signaling.5 The Plexin cytoplasmic region contains a Rho and Ras-family-specific GTPase-activating protein (GAP) domain.6,7 Although several models have been proposed, the exact role of the Ras-GAP activity in Semaphorin signaling remains obscure.5,8,9 However, it has recently been characterized that this GAP domain can be activated by dimerization after Semaphorin binding to Plexin ectodomains.10 This process could in turn inhibit Rap GTP-binding proteins and affect downstream pathways. Additionally, Plexins B and D bear PDZ (post synaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1) and zonula occludens-1 protein (ZO-1))-binding motifs that are most likely involved in protein-protein interactions and downstream signaling.

Neuropilins. The Neuropilin receptors, namely NRP-1 and -2 are only found in vertebrates, where they exist as multiple isoforms, including soluble ones. They operate as receptors or co-receptors for diverse ligands, ranging from class III Semaphorins, heparin-binding proteins and growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF) and placental growth factor 2 (PIGF).11,13 These single transmembrane proteins include five extracellular domains and a short cytoplasmic tail. Their extracellular region contains two complement-like (CUB) domains, also designated a1 and a2
domains, two FV/FVIII coagulation factor-like domains, also known as b1 and b2, and a single meprin/A5-protein/PTPμ (MAM) domain, also called c. The a1/a2 domains are involved in Semaphorin binding, while the b1/b2 part is necessary for VEGF binding.11,14 More specifically, the domain a1 is essential for the stabilization of the class III Sema3-PlexinA interaction and subsequently allows Semaphorins signaling through PlexinA14 (Fig. 1); with the exception of Sema3E which acts via PlexinD1 and can signal in the absence of Neuropilins in endothelial cells.15 The cytoplasmic tail does not harbor enzyme activity per se but rather a PDZ-binding motif, whose function requires further investigation.

**General mode of action of Semaphorins.** Semaphorins have been implicated in a wide variety of functions instrumental in the development of the CNS. These include neuron migration,16 axonal pruning,17,18 synapse formation19 and synaptic transmission.20 Neurons, as with epithelial or endothelial cells, are polarized cells. Indeed, neurons harbor a unique long axon, which is directed by a highly motile structure, named the growth cone, and, multiple shorter dendrites, whose formation is controlled, among others, by Semaphorin 3A (Sema3A). Indeed, this decisive Semaphorin was first characterized for its ability to promote dendrite formation via the inhibition of axon specification.21 The Sema3A co-receptor NRP-1 favors the accumulation of cyclic GMP (cGMP) over AMP and the further inhibition of PKA and GSK3β activities, two crucial signaling pathways for axon development.21 Through this cGMP/AMP balance, Sema3A repels growth cone movement, while stimulating dendrite outgrowth. This action is thought to rely on a protein named Nervy that links PKA to the Sema3A receptor PlexinA. Alternatively, it employs a different set of neuropilin co-receptors.22,25

Another important aspect of Semaphorin action in neuron biogenesis is its impact on the actin cytoskeleton and extracellular matrix adhesion. For instance, class III Semaphorins released into the surrounding environment of a growth cone, triggered Plexin GAP activity upon receptor engagement, which in turn decreases R-Ras activation and integrin attachment.24 This results in the reduction of outgrowth, illustrating the repulsive activity of Semaphorins. On the other edge of the growth cone, the absence of Semaphorins allows higher level of R-Ras activity, and therefore the upregulation of integrin binding that facilitates growth.2,25

The leading edge of migrating cells, such as endothelial or epithelial cells, is comparable to the axon growth cone. Any abnormal changes in the expression of Semaphorins might trigger CNS diseases by affecting neuronal structure,26 as demonstrated in the case of regeneration failure where Sema3A inhibits axon growth at sites of injury.27 It also appears that Semaphorins can contribute to tumor progression,28 a point that will be particularly discussed in this review.

**Effects of Semaphorins on Epithelial Junctions**

Epithelia are located at the boundaries of tissues where they form regulated sealing barriers controlling solute diffusion and immune cell passage. To assume their roles, epithelial cells establish specific junctions that maintain barrier integrity. For instance, in the case of the intestine, epithelial cells protect underlying tissues from luminal content, while permitting the absorption and secretion of fluids and ions. In this context, epithelial cells are polarized; i.e. cell-cell contacts are organized in complexes distributed specifically along the apical-basal axis. Both tight and adherens junctions, as well as desmosomes are found within epithelial intercellular junctions (Fig. 2).

**Epithelial adherens junctions.** Structure and function of E-cadherin. The key protein of adherens junctions (AJ) that is found accumulated at epithelial cell-cell contacts is the transmembrane glycoprotein E-cadherin from the classical cadherin family. Structurally, classical cadherins consist of three different domains: the extracellular domain (ECD), the transmembrane (TM) and the intracellular domain (ICD).29 The ECD is formed by the repetition of five cadherin repeats called EC 1 to 5, from the N-terminal to the C-terminal end. Each EC consists of 110 amino acids organized in β-sheets.30,31 The EC1 domain contains the HAV sequence and is suspected to bear the adhesive specificity and thus to promote homophilic trans-association with adjacent
cells, while the entire ECD likely engages in heterophilic interaction. The ICD is highly conserved among vertebrate cadherins, in terms of sequence, length and cytoplasmic interacting partners. This cytosolic part modulates strength, dynamics and signaling abilities of cadherins at the cell-cell junctions.

**E-cadherin cytoplasmic partners.** The E-cadherin ICD is connected to the actin cytoskeleton through its association with β-catenin, which in turn binds to α-catenin. Finally, α-catenin interacts with actin and several actin-binding adaptors, such as formin, vinculin, α-actinin, afadin and ZO-1, that can modulate actin organization, dynamics and polymerization. Cell-cell contacts can also be strengthened through E-cadherin cis-interaction involving the juxtamembrane region where the p120 catenin serves as a linker. Importantly, epithelial cell-cell contacts still remain plastic, as E-cadherin can undergo endocytosis, recycling, lateral movements and shedding. Tight junctions (TJ) presented in the paragraph below, delimited the apical pole of epithelial cells and accumulated above AJs. At the opposite, basolateral proteins, such as desmosomes, are found below AJs (Fig. 2). Thus, E-cadherin is not uniformly distributed over the cell surface but rather clustered in specific membrane domains within AJs, which serve as signaling platforms. Indeed, AJs can also signal through proteins such as Rho GTPases, tyrosine kinase receptors and other lipid modifications. These interactions contribute to the organization of membrane trafficking and promote polarized growth in regions that can be immediately adjacent or distant from AJs. In this scenario, AJs modulate TJ formation and epithelial polarization and therefore discriminate apical and basolateral subcellular areas.

Overall, one should keep in mind that AJs are not a rigid structure but rather a complex that can integrate and adapt to external changes and morphogenetic movements, including delamination, cell division and epithelial-to-mesenchymal transition (EMT).

**Epithelial tight junctions.** The epithelium is fastened apically by TJs, which almost completely obstruct the paracellular exchange pathway. TJs therefore contribute to the regulation of the ion and fluid passage, while restricting the diffusion of large molecules. In addition to their role as a barrier, TJs can regulate numerous cellular processes such as polarity, proliferation, differentiation and migration. First identified by electronic microscopy in epithelial cells, TJs form typical structures of close apposition between membranes of two adjacent cells. The freeze-fracture method had allowed the observation of focal hemifusion sites associated with intracellular fibrils. This highlights the interplay between transmembrane proteins, cytosolic partners and the cytoskeleton.

**Structure and functions of transmembrane proteins.** TJs are enriched with many transmembrane proteins that associate to each other and link to scaffolding proteins and the actin cytoskeleton. Three protein families are found in TJs: claudins, occludin and junctional adhesion molecules (JAMs).

**Claudins** are calcium independent cell-cell adhesion proteins, comprising at least 24 members, which regulate paracellular permeability. They are instrumental in the maintenance of barrier integrity, as demonstrated by severe barrier defects in knockout mice lacking individual claudin family members. Interestingly, claudins exhibit organ and tissue specific expression patterns, thus forming a large repertoire of TJs with different strength, size and ion specificity.

Occludin was the first protein identified as a TJ component. Occludin is a tetraspan membrane protein bearing a MARVEL domain (MAL and related proteins for vesicle trafficking and membrane link). Its role is not fully understood, but in vitro studies agree that this junctional protein operates at the epithelial barrier and functioned as a signaling protein. Finally JAMs, the third group of proteins found at TJs, consist of single transmembrane proteins that belong to the immunoglobulin superfamily. They are composed of two extracellular immunoglobulin-like domains, a single transmembrane region and a C-terminal part. Among them, JAM-A, -B, -C and -D and the Coxsackie and adenovirus receptor (CAR), are found at...
epithelial junctions. JAMs can be engaged either in either homo- or hetero-philic adhesions within the TJs. However, they cannot form TJs by themselves when expressed in fibroblasts. Although their exact function is still uncertain, JAMs, similarly to claudins and occludin, can bind to cytoplasmic scaffolding partners.

**Scaffolding proteins.** Among all cytosolic proteins involved at the cytoplasmic surface of TJs, the major components are the zona occludens (ZO), designated as ZO-1, ZO-2 and ZO-3.

These proteins share sequence similarity and molecular organization, as they all contain three PDZ domains and one Src-homology 3 (SH3) domain followed by one guanylate kinase-like (GUK) domain involved in protein-protein interactions. Through the N-terminal PDZ domains, ZOs interact directly with JAMs, occludin and claudins, while they are connected to the cytoskeleton via their C-terminal tail. ZO-1 was found to be crucial for epithelial barrier function. This protein also serves as scaffold for regulatory proteins such as kinases, GTP exchange factors (GEF) and many transcription factors. Many other PDZ-containing proteins have since been discovered to be cytoplasmic components of the TJs, including membrane-associated guanylate kinases (MAGI-1, -2, -3), Multi-PDZ domain protein 1 (MUPP1), cingulin and polarity proteins PAR3/6, and will not be discussed in details here.

These TJ components, much like the cytoplasmic partners for AJs, are pivotal for the epithelial biology. They exhibit the ability to link many transmembrane proteins to the cytoskeleton, promote signals toward other cellular compartments and adapt the cellular responses to external cues.

**Semaphorins and the epithelial barrier function.** At present, knowledge concerning Semaphorins in epithelial barrier function, and in particular their direct action on junctional components, is quite limited. This review will instead present selected cases that support for a role of individual Semaphorin in the reinforcement of epithelial barrier components, or, at the opposite end, favor barrier dismantlement, especially in the course of cancer progression (Fig. 2).

**Pro-barrier Semaphorins.** During lung organogenesis, layers of progenitors lining the developing airways maintain their epithelial characteristics, while proliferating and differentiating into multiple cell types. Many genes that establish and maintain cell polarity and/or cell junctions are regulated. In this context, it has been shown that class 3 Semaphorins, namely Sema3A, Sema3C and Sema3F, display a specific spatiotemporal distribution in lung epithelial cells. Organ culture analyses have shown that Sema3C and Sema3F positively regulate branching and promote epithelial proliferation, whereas Sema3A leads to a reduced number of terminal pulmonary buds. Altogether these data suggest that a repertoire of Semaphorins may orchestrate lung epithelial morphogenesis, a process that might culminate in the regulation of the epithelial barrier architecture.

As Sema3B is concerned, this gene was characterized to be inactivated in lung cancer and metastatic variants, while its expression in lung and breast cancers induces growth inhibition and apoptosis activation. In a more recent study, the Grainyhead-like (Grhls) transcription factors were proposed to function upstream of Semaphorins in lung development. These factors regulate cell-cell adhesion molecule expression, for instance, Grhl3 controls claudin1 and occludin transcription, while Grhl2 positively affects E-cadherin and claudin4 levels. Grhl2 was also described to modulate Sema3B and Sema3C expression, both directly and indirectly, plus that of their corresponding receptor NRP-2. Indeed, Grhl2 downregulation correlated with Sema3B, Sema3C and NRP-2 decrease that in turn could impact gene expression of apical junction proteins. Although the signaling mechanisms involved have not been fully characterized, Sema3B and Sema3C might emerge as important positive mediators of lung epithelial barrier integrity.

As mentioned above, the lung epithelium is also modulated by Sema3F, which is expressed in lung epithelial cells together with NRP-1 and -2. Interestingly, Sema3F and Sema3B map into 3p21.3, a region frequently downregulated in small cell lung cancer and breast carcinoma. In their study, Brambilla E. and colleagues describe Sema3F distribution in normal lung and several lung epithelial cancer cell lines. In normal epithelial cells, Sema3F localizes predominantly at the apical face. In the case of low-grade tumor cells, with little to no locomotion, Sema3F accumulated at the interface of adjacent cells, in a region evocative of AJs. In contrast, in high-grade tumor cells, Sema3F expression was considerably reduced and remained mainly in the cytoplasm and in motile regions, such as lamellipodia and protrusions. Nasarre and colleagues have further focused on the functional role of Sema3F during the course of breast cancer progression. Using poorly to highly motile cancer cells, a different expression pattern of Sema3F and its receptors was first highlighted. Low levels of Sema3F, NRP-1 and NRP-2 were found in motile cells, whereas less motile cells release more Sema3F and NRP-1 was the unique receptor being expressed. Interestingly Sema3F is thought to have a repulsive activity on highly motile cells, operating in an NRP-2-dependent manner. In less motile cancer cells, addition of Sema3F induced an NRP-1-dependent delocalization of membrane E-cadherin and β-catenin. No impact on N-cadherin expression was however detected. It has thus been hypothesized that Sema3F could dampen tumor progression. Although not completely elucidated, the mechanism underlying the switch from high to low Sema3F expression in cancer cells, and its associated redistribution, might involve VEGF, a potential Sema3F binding competitor for Neuropilins. Indeed, loss of Sema3F membrane expression correlated with high levels of VEGF. In this scenario, Sema3F reduction and cytoplasmic sequestration could facilitate VEGF receptor activation and associated migratory responses.

Similarly to its putative role in the lung epithelium barrier morphogenesis, Sema3A could affect as well differentiation processes in the corneal epithelium. Sema3A, together with its receptors PlexinA1 and NRP-1 are expressed in the cornea. The works by Nishida group demonstrate that Sema3A released from surrounding corneal fibroblasts triggers an upregulation in the membrane expression of E- and N-cadherins in corneal epithelial cells. In a wound-healing model, NRP-1 and Sema3A levels were increased, in association with epithelial thickening. However, Sema3A was not colocalized within junctional proteins such as ZO-1, occludins, E-cadherin and β-catenin.
Beside their impact on adhesion molecules, Semaphorins also regulate actin at motile structures, comparable to neuron growth cones. Altogether these observations suggest that Semaphorins might emerge as modulators of cell-cell adhesion and migration during development and maturation of specialized epithelia, while their aberrant expression and/or function is involved in the course of cancer progression.

Anti-barrier Semaphorins. In opposition to the roles of class III Semaphorins in epithelial junction reinforcement are other Semaphorins that participate in epithelial junction dissociation (Fig. 2). Normal and tumor epithelial liver cells express PlexinB1, which mediates cell scattering upon Sema4D stimulation. This mechanism triggers cell-cell dissociation and subsequent cell migration, in a manner similar to the effect of scatter factor (SF-1), the ligand for the receptor encoded by the Met proto-oncogene. Indeed, while Sema4D acts primarily through PlexinB1, the signal transduction leading to cell dissociation and invasive growth rather implied the tyrosine kinase activity of Met. Moreover, this mechanism was not restricted to the liver but was also unveiled in pancreatic, lung and mammary epithelial tumor cell lines. This original signaling complex, which is formed between tyrosine kinase receptors and Plexins is modulated by Semaphorins, and impacts on epithelial cell junctions and therefore aggressiveness of tumor cells.

In a comparable manner, Sema7A was described to be instrumental for EMT in mammary epithelial cells. Indeed, Sema7A was suggested to be required for TGF-β-induced EMT through E-cadherin downregulation. Furthermore, the Sema7A promoter contains tandem Ets-binding sites, which can be repressed by Ets-2-repressor factor (ERF), suggesting a point of convergence with TGF-β signaling, which is also inhibited by ERF. Additionally, Sema7A might play a role in cell motility through β1-integrin interaction and PlexinC1 signaling. Thus, Sema7A appears to be an important modifier of epithelial cell adhesion.

Finally, the role of Sema3E, also known as Semaphorin H, was recently highlighted in epithelial barrier integrity. This signaling molecule, together with its receptor PlexinD1, are dramatically upregulated in high-grade tumor cells, when compared with normal and low-grade tumors, especially in ovarian and colon epithelial cancer cells. It has been suggested that Sema3E expression drives cancer and metastasis progression through several crucial steps such as EMT, invasion into the extracellular matrix, extravasation and metastatic colonies formation. For instance, Sema3E and PlexinD1 signaling have been demonstrated to drive Snail1 nuclear relocalization, in correlation with E-cadherin downregulation and vimentin upregulation, crucial events in cancer EMT. In addition, Sema3E can activate the ErbB2 tyrosine kinase receptor via its phosphorylation, which in turn triggers MAPK, PLC-γ and PI3K pathways that collectively induce massive cytoskeletal rearrangement and increased cell motility. Notably, Sema3E-expressing tumor cells also provoke extracellular matrix degradation, in areas that colocalize with actin-rich structures characterized as invadopodia. Likewise, such cells possess filopodia and lamellipodia, a round-shaped morphology and increased migration capacity. Overall, these data converge on the idea that Sema3E can affect epithelial barrier integrity by disrupting among others, E-cadherin.

To conclude, Semaphorin expression is modulated during physiological and pathological epithelial morphogenesis. Although molecular mechanisms are still under investigation, their signaling activity impacts on cell-cell junction organization. These molecules could thus represent promising candidates for novel therapeutic targets in cancers.

Effects of Semaphorins on Endothelial Junctions

The vascular endothelium forms an interface between circulating blood and irrigated tissues. Endothelial cells are paramount to vascular biology and control the distribution of molecules and cells, as well as waste release throughout the body. The intercellular endothelial junctions primarily contain TJs and AJs, and restrict bidirectional passage between the blood compartment and underlying tissues. Unlike epithelial junctions, endothelial junctions exhibit a more flexible organization, where TJs and AJs are found intertwined along the cell-cell contact zone (Fig. 3).

Endothelial tight junctions. Collectively TJs formed approximately 20% of the total cellular junctions in endothelial cells, and allow strong electrical resistance and low permeability. Endothelial TJs are organized around adhesion proteins from the same families than those found in epithelial cells, although the isoforms expressed and the associated partners diverge. For instance, the claudin family comprises more than 20 members, however only a few are found in endothelial cells; such as only claudin-3, -5 and -12 that are expressed in the brain endothelium. Of note, claudin5 knockout mice have normal TJs with an increased permeability in brain vasculature territories.

As in epithelial junctions, other transmembrane proteins compose TJs, namely occludin and JAMs. Ocludin is particularly enriched in the brain microvasculature, in corroboration with stronger tissue barrier function. However, loss of occludin alone in mice is not sufficient in mouse model to impact on vascular permeability. Endothelial JAMs, namely JAM-A, -B, -C, ESAM (endothelial cell specific adhesion molecule), CD146 (melanoma cell adhesion molecule MCAM or cell surface glycoprotein MUC18) and PECAM (platelet endothelial cell adhesion molecule or CD31) are also recruited to cell-cell contacts. Their level of expression, localization and interaction with extracellular ligands might vary in response to permeability factors, involved in either angiogenesis and/or immune responses. For instance, histamine and VEGF promote JAM-C relocalization into cell-cell contacts, where it could in turn modulate the stability of the vascular cell-to-cell adhesion molecule, Vascular Endothelial (VE)-cadherin.

Endothelial adherens junctions. AJs contribute to the initiation and stabilization of cell-cell adhesion, as well as regulation of the actin cytoskeleton and intracellular signaling. They are mainly composed by VE-cadherin, which belongs to the calcium-dependent adhesion molecule family (see Fig. 3). Similarly to classical cadherins, VE-cadherin binds to p120-catenin and β-catenin, which bridges the cadherin-catenin complex to the actin cytoskeleton via α-catenin. VE-cadherin is ubiquitously and...
specifically expressed in the vascular endothelium. Importantly, VE-cadherin deletion in mice induces embryonic death because of vascular system defects; in other words, VE-cadherin is essential for the formation of stable, mature vessels. Moreover, VE-cadherin blocking antibodies provoke an increase of microvascular permeability, while its stability at the junctions opposes VEGF-mediated permeability. In addition, VE-cadherin modulates signaling pathways that affect the overall TJ architecture and organization. Hence VE-cadherin is the target of many molecular pathways involved in vascular leakage.

Vascular permeability is finely tuned in quiescent vessels and adapts to many challenges in the perivascular microenvironment including angiogenesis, shear stress, flow and inflammation. The intercellular junctions, and especially VE-cadherin, actively contribute to these modifications in the vascular barrier. Indeed, VE-cadherin integrity can be altered by multiple means, including phosphorylation, destabilization of catenin interaction, internalization, shedding and acto-myosin contractility, all of which ultimately converge on increased endothelial permeability.

**Semaphorins and the endothelial barrier.** Semaphorin family members have emerged as important molecular modifiers of both neural fate and endothelial biology, largely by operating a fine tuned combination of attractive and repulsive signals. Indeed, cancer cells release pro-angiogenic Semaphorins, such as Sema4D, that are able to promote endothelial migration and vascular invasion within the tumor mass. By contrast, class III Semaphorin expression is generally reduced in cancers; they normally function as general inhibitors of angiogenesis. Semaphorin 3A. Beside its axon guidance properties, Sema3A controls vessel formation by inhibiting integrin function. It is also suspected to act as an anti-angiogenic factor. However, while most anti-angiogenic proteins oppose permeability, Sema3A, paradoxically, increases vascular permeability (Fig. 4). The signaling mechanisms mediating this effect involve the destabilization of VE-cadherin through tyrosine and serine phosphorylations. From a molecular standpoint, Sema3A permeability action depends on NRP-1 and PlexinA1 receptors, independently of VEGF. However, divergent downstream molecular pathways have been reported depending on the endothelial context, i.e. macro- vs. micro-vascular cells. In a first study, Sema3A was found to induce permeability via the PI3Kγ-δ/Akt pathway, independently of Src via NRP-1. Another study from our lab established that tumor-released Sema3A provoked serine 665 phosphorylation of VE-cadherin and endothelial junction disorganization, thereby leading to increased endothelial permeability. In microvascular brain endothelial cells, Sema3A operates via Src phosphorylation and activation, recruitment of Set, a potent inhibitor of the serine/threonine Protein Phosphatase 2A (PP2A), and inhibition of PP2A phosphatase activity. The Sema3A pathway is then subsequently involved in the dissociation of a constitutive PP2A/VE-cadherin interaction that might operate to secure VE-cadherin junctions in quiescent endothelial cells. To conclude, Sema3A exerts pro-permeability action through targeting VE-cadherin at the endothelial junctions as a means to modulate local disruption of the endothelial barrier.

**Semaphorin 3F.** Sema3F is a well-characterized repulsive molecule in endothelial cells, and could be a potential candidate for anti-angiogenic therapies. However, it has been recently proposed that hypoxia opposes Sema3F anti-angiogenic action and signaling activity in endothelial cells by downregulating the levels of NRP-2. This ultimately favors VEGF-paracrine function and therefore angiogenesis. Nonetheless, in poorly vascularized tumors, such as schwannomas, Sema3F overexpression could enhance pericyte coverage and decrease vascular permeability. Therefore, these findings suggest that depending on the tumor context, Sema3F could act as a vascular normalization agent.

**Semaphorin 7A.** Sema7A is reported to take part in immune responses and inflammation. Interestingly, Sema7A increases transmigration of polymorphonuclear neutrophils across endothelial layers. This effect relies on the endothelial expression of Sema7A, rather than a direct action on leukocytes. Moreover, Evan’s blue experiments demonstrated that hypoxia-induced vascular leakage was attenuated in Sema7A knockout mice. Likewise, mice lacking Sema7A exhibited decreased blood-brain
barrier permeability upon West Nile virus infection and were thus protected. These results were also recapitulated in human cell models for West Nile virus infection using a Sema7A blocking antibody, thus pointing toward a role of Sema7A at the crossroads between endothelial biology and immunology.

Class III Semaphorins in particular were recently highlighted for their anti-angiogenic properties, as well as their remarkable ability to impact on endothelial barrier properties (Fig. 3). Although the signaling mechanisms are not fully elucidated, this interplay between Semaphorins and intercellular junctions opens a new field of investigation in endothelial biology.

Epithelial and endothelial junctions function as keystones in the organization and integrity of tissue barriers. They accomplish this by modulating the biology of the epithelium and endothelium through a finely tuned combination of multiple inside-out and outside-in signals. In pathological conditions, such as cancer progression, misexpression of junctional proteins and/or their dysfunction are frequently observed. In this context, Semaphorins could guide the dismantlement of cell-cell contacts, or, at the opposite end, reinforce the intercellular junctions. Although research efforts are still required to better understand the combinatorial actions of Semaphorins, Plexins and Neuripins and their associated molecular signaling in epithelial and endothelial barriers, targeting them will offer new opportunities for future cancer therapies.

Disclosure of Potential Conflicts of Interest
The authors have declared that no competing interests exist.

Acknowledgments
The authors thank members of JG laboratory, in particular Dr Julie Dwyer, for comments on the manuscript, and Fondation ARC pour la Recherche sur le Cancer, Fondation pour la Recherche Medicale, Ligue Nationale contre le Cancer Comite de Paris, Centre National pour la Recherche Scientifique, Marie Curie Actions within the 7th framework program for research and Universite Paris Descartes for financial support.

References
1. Luo Y, Rabille D, Raper JA. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993; 75:217-27; PMID:8402908; http://dx.doi.org/10.1016/0092-8674(93)80864-L.
2. Semaphorin Nomenclature Committee. Unified nomenclature for the semaphorins/collapsins. Cell 1999; 97:551-2; PMID:10367884; http://dx.doi.org/10.1016/S0092-8674(99)80766-7.
3. Janssen BJ, Robinson RA, Perez-Branguli F, Bell CH, Mitchell KJ, Siebold C, et al. Structural basis of semaphorin-plexin signalling. Nature 2010; 467:1118-22; PMID:20877282; http://dx.doi.org/10.1038/nature09468.
4. Capparuccia L, Tamagnone L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment—two sides of a coin. J Cell Sci 2009; 122:1723-36; PMID:19461072; http://dx.doi.org/10.1242/jcs.030197.
5. Nogí T, Yasui N, Mihara E, Matsunaga Y, Noda M, Yamashita N, et al. Structural basis for semaphorin signaling in the plexin receptor. Nature 2010; 467:1123-7; PMID:20881961; http://dx.doi.org/10.1038/nature09473.
6. Hu H, Marton TF, Goodman CS. Plexin B mediates axon guidance in Drosophila by simultaneously inhibiting active Rac and enhancing RhoA signaling. Neuron 2001; 32:59-51; PMID:11604137; http://dx.doi.org/10.1016/S0896-6273(01)00453-6.
7. Oinuma I, Ishikawa Y, Katoh H, Negishi M. The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. Science 2004; 305:862-5; PMID:15297763; http://dx.doi.org/10.1126/science.1097545.
8. He H, Yang T, Terman JR, Zhang X. Crystal structure of the plexin A3 intracellular region reveals an autoinhibited conformation through active site sequestration. Proc Natl Acad Sci U S A 2009; 106:15610-5; PMID:19717441; http://dx.doi.org/10.1073/pnas.0906923106.
9. Bell CH, Aricescu AR, Jones EF, Siebold C. A dual binding mode for RhoGTPases in plexin signalling. PLob Biol 2011; 9:e1001134; PMID:21921513; http://dx.doi.org/10.1371/journal.pbio.1001134.
10. Wang Y, He H, Srivastava N, Vikarunnessa S, Chen YB, Jiang J, et al. Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. Sci Signal 2012; 5; PMID:22253263; http://dx.doi.org/10.1126/scisignal.2002636.
11. He Z, Tessler-Lavigne M. Neuripin is a receptor for the axonal chemorepellent Semaphorin III. Cell 1997; 90:739-51; PMID:9288753; http://dx.doi.org/10.1016/S0092-8674(00)80534-6.
12. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999; 99:71-80; PMID:10520995; http://dx.doi.org/10.1016/S0092-8674(00)80063-X.
13. Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, et al. Plexin-neuripin-1 complexes form functional semaphorin-3A receptors. Cell 1999; 99:59-69; PMID:10520994; http://dx.doi.org/10.1016/S0092-8674(00)80062-8.
14. Janssen BJ, Malinauskas T, Weir GA, Cader MZ, Siebold C, Jones EF. Neuripins lock secreted semaphorins onto plexins in a ternary signaling complex. Nat Struct Mol Biol 2012; 19:1293-9; PMID:23104057; http://dx.doi.org/10.1038/nsmb.2416.
15. Gu C, Yoshida Y, Liver J, Reimerr DV, Mann E, Mere J, et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005; 307:265-8; PMID:15550623; http://dx.doi.org/10.1126/science.1105416.
16. Chen G, Sima J, Jin M, Wang KY, Xue XJ, Zheng W, et al. Semaphorin-3A guides radial migration of cortical neurons during development. Nat Neurosci 2008; 11:36-44; PMID:18059265; http://dx.doi.org/10.1038/nn.2018.
17. Renaud J, Kerjan G, Sumita I, Zagar Y, Georget V, Kim D, et al. Plexin-A2 and its ligand, Sema6A, control nucleus-centrosome coupling in migrating granule cells. Nat Neurosci 2008; 11:440-9; PMID:18327254; http://dx.doi.org/10.1038/nn.2064.
18. Bagri A, Cheng HJ, Yaron A, Pleasure SJ, Tessler-Lavigne M. Stereotyped pruning of long hippocampal axon branches triggered by retraction inducers of the semaphorin family. Cell 2003; 113:285-99; PMID:12732138; http://dx.doi.org/10.1016/S0092-8674(03)00267-8.
19. Leslie JR, Imai F, Fukahara K, Takeghahara N, Rizvi TA, Friedel RH, et al. Ectopic myelinating oligodendrocytes in the dorsal spinal cord as a consequence of altered semaphorin 6D signaling inhibit synapse formation. Development 2011; 138:4085-95; PMID:2183918; http://dx.doi.org/10.1242/dev.066076.

20. Sahay A, Kim CH, Sepkuty JP, Cho E, Huganir RL, et al. A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. Nat Med 2010; 16:533-42; PMID:20453849; http://dx.doi.org/10.1038/nm1965.

21. Zhao J, Chao DW, Yang Z, Zhang Y, Sivasankar S, Nelson WJ, Chu S. Resolving complex interactions are disrupted. Cell Death Dis 2012; 3:1102-17; PMID:23223933; http://dx.doi.org/10.1038/cddis.2012.14.

22. Itoh M, Sasaki H, Nakayama M, et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006; 126:741-54; PMID:1629393; http://dx.doi.org/10.1016/j.cell.2006.04.045.

23. Matter K, Bals M. Epithelial tight junctions, gene expression and nuclear- junctional interplay. J Cell Sci 2007; 120:1505-11; PMID:17452262; http://dx.doi.org/10.1242/jcs.005975.

24. Farquhar MG, Palade GE. Junctional complexes in various epithelia. J Cell Biol 1956; 17:577-602; PMID:13944428; http://dx.doi.org/10.1083/jcb.17.2.577.

25. Oinuma I, Katoh H, Negishi M. Molecular dissection of the semaphorin 4D receptor plexin-B1-stimulated R-Ras GTPase-activating protein activity and neuron remodeling in hippocampal neurons. The Journal of Neuroscience 2004; 24:11743-80.

26. Mann F, Chauvet S, Rougon G. Semaphorins in development and degeneration of the brain: Implication for neurological diseases. Prog Neurobiol 2002; 67:57-79; PMID:12735764; http://dx.doi.org/10.1016/S0079-6183(02)00102-X.

27. Sánchez-Pedrás J, Peralta-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in semaphorin 6D signaling inhibit synapse formation. Development 2011; 138:4085-95; PMID:2183918; http://dx.doi.org/10.1242/dev.066076.
70. Brambilla E, Constantin B, Drabkin H, Roche J. Altered fertility. Hum Mol Genet 2011; 20:4759-74; http://dx.doi.org/10.1093/hmg/ddr120.

71. Nazeri Y, Kazemi B, Dabirifard M, Mohseni I. Semaphorin 3F expression in human breast cancer cell lines. Cell Biol Int 2009; 33:137-43; http://dx.doi.org/10.1016/j.cellbi.2008.12.003.

72. Zhou Y, Li G, Shi Y, Xing W, Wang J, Chen H, Wang Y, Li X, Zhang J, Zhao J, et al. Discovery of frequent homozygous inactivations of the PTPRB gene in lung cancer. Sci China Life Sci 2010; 53:232-41; http://dx.doi.org/10.1007/s11427-010-0026-1.

73. McArthur K, Kwon J, McEvoy L, et al. Endothelial adherens junction function and structure in claudin-5-deficient mice. J Cell Biol 2012; 204:99-111; http://dx.doi.org/10.1083/jcb.201109127.

74. Konno K, Kwon J, McEvoy L, et al. Claudin-5 regulates barrier function in endothelial cells. J Cell Biol 2012; 204:91-9; http://dx.doi.org/10.1083/jcb.201109099.

75. Gavard J, Gutkind JS. VEGF controls endothelial cell permeability by promoting the beta-arrestin-dependent endocytosis of VEGF-receptor. Nat Cell Biol 2006; 8:1223-34; http://dx.doi.org/10.1038/ncb1486.

76. Uchida Y, Grossi RR, Fiepatrice P, Rochford KD, Guinan AE, Murphy A, et al. Stabilization of brain microvascular endothelial barrier function by shear stress involves VEGF signaling leading to modulation of P-fy-Fc-receptors. J Cell Physiol 2012; 226:9555-63; http://dx.doi.org/10.1002/jcp.22504; http://dx.doi.org/10.1002/jcp.22655.

77. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, et al. Endothelial adherens junctions control tight junctions by VEGF-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 2008; 10:923-34; http://dx.doi.org/10.1038/ncb1752.

78. Le Guer S, Dwyer J, Gavard J. Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Cell Biol Int 2011; 35:593-605; http://dx.doi.org/10.1002/cbin.10669.

79. Wei SS, Cheres DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437:497-504; http://dx.doi.org/10.1038/nature04397.

80. Wang S, Shima DT, Shimizu T, Watanabe R, Wood M, Cravens A, et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004; 113:885-94; http://dx.doi.org/10.1172/JCI200424241.

81. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 2006; 439:193-203; http://dx.doi.org/10.1038/nature04587.

82. Basile JR, Holmbeck K, Busch TG, Gutkind JS. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D. J Cell Biol 2007; 178:8888-95; http://dx.doi.org/10.1083/jcb.200702132.

83. Basile JR, Gavard J, Gutkind JS. Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J Biol Chem 2007; 282:6031-9; http://dx.doi.org/10.1074/jbc.M606952200.

84. Ballegooijen MA, Drinkwater PN, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vascularization in transgenic mouse models. J Clin Invest 2009; 119:3536-72; http://dx.doi.org/10.1172/JCI36512.

85. Pushkarsky A, Kessler O, Abramovich S, Kigel B, Zaltsman S, Leslie J, et al. Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and Rac. Mol Cell Biol 2010; 30:3806-98; http://dx.doi.org/10.1128/MCB.00639-10.

86. Shima DT, Watanabe RM, Cravens A,et al. Semaphorin 3E initiates angiogenic signaling through plexin D1 by regulating Arf6 and Rac. Mol Cell Biol 2010; 30:3806-98; http://dx.doi.org/10.1128/MCB.00639-10.

87. Shima DT, Watanabe RM, Cravens A, et al. Semaphorin 3E initiates angiogenic signaling through plexin D1 by regulating Arf6 and Rac. Mol Cell Biol 2010; 30:3806-98; http://dx.doi.org/10.1128/MCB.00639-10.
109. Sabag AD, Bode J, Fink D, Kigel B, Kugler W, Neufeld G. Semaphorin-3D and semaphorin-3E inhibit the development of tumors from glioblastoma cells implanted in the cortex of the brain. PLoS One 2012; 7:e42912; PMID:22936999; http://dx.doi.org/10.1371/journal.pone.0042912.

110. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003; 424:391-7; PMID:12879061; http://dx.doi.org/10.1038/nature01784.

111. Acvedo LM, Barillas S, Weiss SM, Gonthier JR, Chenes DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008; 111:2674-80; PMID:18180379; http://dx.doi.org/10.1182/blood-2007-08-110205.

112. Le Guèbe A, Galan-Moya EM, Dwyer J, Tierps J, Kettler G, Hebda JK, et al. Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J Cell Sci 2012; 125:4157-46; PMID:22685328; http://dx.doi.org/10.1242/jcs.108282.

113. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, et al. Semaphorin 3F, a chemorepulsion for endothelial cells, induces a poorly vascularized, nonmetastatic tumor phenotype. J Clin Invest 2004; 114:1260-71; PMID:15520858.

114. Gutmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007; 282:26294-305; PMID:17569671; http://dx.doi.org/10.1074/jbc.M609711200.

115. Coma S, Shimizu A, Klagsbrun M. Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2. Cell Adh Migr 2011; 5:266-75; PMID:21610314; http://dx.doi.org/10.4161/cam.5.3.16294.

116. Wong HK, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AT, di Tomaso E, et al. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. Neoplasia 2012; 14:84-94; PMID:22431917.

117. Kang HR, Lee CG, Homer RJ, Elias JA. Semaphorin 7A plays a critical role in TGF-beta1-induced pulmonary fibrosis. J Exp Med 2007; 204:1083-93; PMID:17485510; http://dx.doi.org/10.1084/jem.20061273.

118. Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takahara N, Takamatsu H, et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature 2007; 446:680-4; PMID:17377534; http://dx.doi.org/10.1038/nature05652.

119. Morote-Garcia JC, Napiwotzky D, Kohler D, Rosenberger P. Endothelial Semaphorin 7A promotes neutrophil migration during hypoxia. Proc Natl Acad Sci U S A 2012; 109:14146-51; PMID:22891341; http://dx.doi.org/10.1073/pnas.1202165109.

120. Sultana H, Neelakanta G, Foellmer HG, Montgomery RR, Anderson JE, Koski RA, et al. Semaphorin 7A contributes to West Nile virus pathogenesis through TGF-beta1/Smad6 signaling. J Immunol 2012; 189:3150-8; PMID:22431917; http://dx.doi.org/10.4049/jimmunol.1201140.